Amgen Inc. (AMGN)

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks t...

Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the ...

Excited to announce dividend hikes for 23 companies, including dividend kings SJW Group and California Water Service Group, with 5% and 7.1% increases. Companies with consistent dividend growth indica...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as a ho...

The stock is up 15% since late December.

Amgen is a "buy" due to its strong earnings beat, attractive dividend, and technical chart pattern forecasting positive future performance. I prioritize a balanced approach, focusing on risk and rewar...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. The company faces significant patent expiries but aims to offset losses with...

Amgen Inc.'s Q4 2024 earnings beat expectations, with 11% YoY revenue growth and 13% EPS increase, showcasing robust performance for the company's growth strategy. Amgen's diversified portfolio includ...

On Tuesday, Amgen Inc AMGN reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the consensus of $8.9 billion.

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.